8 Gene Editing Applications Moving from Lab to Clinical Use

6. HIV Treatment and Prevention - Editing for Viral Resistance

The application of gene editing to HIV treatment and prevention represents a groundbreaking approach to combating one of the world's most persistent viral pandemics, offering the potential for functional cures rather than lifelong antiretroviral therapy. HIV's ability to integrate into the host genome and establish latent reservoirs has made it notoriously difficult to eliminate from infected individuals, but gene editing technologies are providing new strategies to either remove the virus or render cells resistant to infection. The most promising approach involves editing the CCR5 gene in T cells, creating cells that are naturally resistant to HIV infection, similar to the rare individuals with natural CCR5 mutations who are protected from HIV. Clinical trials are exploring both therapeutic applications, where T cells from HIV-positive patients are edited and reinfused to create a resistant immune system, and preventive applications for high-risk individuals. Additionally, researchers are investigating direct targeting of HIV DNA integrated into the host genome using CRISPR-Cas9 to excise viral sequences from infected cells. Companies like American Gene Technologies and Excision BioTherapeutics are advancing these approaches through clinical development, with early results showing successful gene editing and some evidence of viral load reduction. The complexity of HIV treatment lies in the virus's genetic diversity and its ability to hide in various tissue reservoirs throughout the body, requiring sophisticated delivery methods and comprehensive targeting strategies. Beyond individual treatment, gene editing approaches to HIV could potentially contribute to population-level prevention strategies, particularly in regions with high HIV prevalence, representing a paradigm shift from treatment to prevention and potentially contributing to the eventual elimination of HIV as a public health threat.